Bayer Return on Tangible Equity 2010-2024 | BAYRY

Current and historical return on tangible equity values for Bayer (BAYRY) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Bayer Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2024-06-30 $-3.32B $-21.58B 14.19%
2024-03-31 $-3.35B $-22.09B 13.75%
2023-12-31 $-3.18B $-24.44B 12.92%
2023-09-30 $-4.25B $-25.58B 16.93%
2023-06-30 $1.28B $-25.34B -4.96%
2023-03-31 $3.02B $-23.17B -11.15%
2022-12-31 $4.37B $-26.24B -14.98%
2022-09-30 $5.30B $-28.18B -16.32%
2022-06-30 $4.85B $-30.59B -13.78%
2022-03-31 $2.36B $-31.70B -6.36%
2021-12-31 $1.18B $-39.27B -3.12%
2021-09-30 $-0.10B $-39.05B 0.26%
2021-06-30 $-3.41B $-38.19B 9.53%
2021-03-31 $-11.11B $-34.82B 30.72%
2020-12-31 $-11.99B $-35.88B 34.85%
2020-09-30 $-10.51B $-34.02B 32.05%
2020-06-30 $-6.15B $-39.99B 18.96%
2020-03-31 $4.82B $-27.71B -15.84%
2019-12-31 $4.58B $-29.48B -14.66%
2019-09-30 $-1.69B $-32.60B 5.23%
2019-06-30 $0.51B $-31.84B -1.62%
2019-03-31 $1.01B $-31.08B -3.14%
2018-12-31 $2.00B $-33.95B -9.76%
2018-09-30 $7.49B $-29.34B -82.42%
2018-06-30 $8.69B $-34.42B -268.96%
2018-03-31 $9.08B $15.63B 124.55%
2017-12-31 $8.29B $11.80B 426.93%
2017-09-30 $7.98B $-5.93B -1778.50%
2017-06-30 $4.75B $7.67B -1269.57%
2017-03-31 $4.96B $-5.77B -123.39%
2016-12-31 $5.02B $2.23B -123.25%
2016-09-30 $5.26B $-5.63B -84.19%
2016-06-30 $5.04B $-6.91B -69.33%
2016-03-31 $4.76B $-5.97B -56.99%
2015-12-31 $4.56B $-6.47B -44.74%
2015-09-30 $4.06B $-9.75B -32.62%
2015-06-30 $4.04B $-11.21B -40.00%
2015-03-31 $4.08B $-13.36B -53.68%
2014-12-31 $4.55B $-15.42B -108.49%
2014-09-30 $4.99B $-0.43B 1503.24%
2014-06-30 $4.86B $-1.15B 654.15%
2014-03-31 $4.65B $0.22B 440.52%
2013-12-31 $4.24B $2.69B 316.28%
2013-09-30 $4.08B $1.21B 673.55%
2013-06-30 $3.77B $0.10B 1978.98%
2013-03-31 $3.30B $1.35B 7723.98%
2012-12-31 $3.15B $-0.24B 5644.84%
2012-09-30 $3.21B $-0.45B 6137.80%
2012-06-30 $3.46B $-0.49B -172750.00%
2012-03-31 $3.90B $1.40B -8607.73%
2011-12-31 $3.45B $-0.26B -900.98%
2011-09-30 $2.72B $-0.66B -367.69%
2011-06-30 $2.17B $-0.66B -153.99%
2011-03-31 $1.77B $0.05B -83.62%
2010-12-31 $1.75B $-1.68B -62.21%
2010-09-30 $2.16B $-3.35B -65.76%
2010-06-30 $2.18B $-3.47B -60.65%
2010-03-31 $2.23B $-2.73B -58.36%
2009-12-31 $1.87B $-3.62B -39.02%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94